Announced details
B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) and Waldenström macroglobulinemia (WM)
The relationship involves presenting clinical trial data on docirbrutinib, which the company is developing, at the Annual Meeting. Capital, personnel and business relationships: Not disclosed.
A medical society in the field of hematology. Location, representative, capital and year established: Not disclosed.
New Orleans, Louisiana, U.S. (venue of the ASH Annual Meeting)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Presentation information for the 68th Annual Meeting of the American Society of Hematology; abstract URLs (presentation numbers 3878 and 1815)
| Item | Details |
|---|---|
| Names of Products / Services Covered | docirbrutinib（AS-1763） |
| Counterparty | American Society of Hematology (ASH) |
| Counterparty overview | A medical society in the field of hematology. Location, representative, capital and year established: Not disclosed. |
| Relationship with the Company | The relationship involves presenting clinical trial data on docirbrutinib, which the company is developing, at the Annual Meeting. Capital, personnel and business relationships: Not disclosed. |
| Launch date | 12 and 13 December 2026 (scheduled presentation dates) |
| Applicable area | B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) and Waldenström macroglobulinemia (WM) |
| Location | New Orleans, Louisiana, U.S. (venue of the ASH Annual Meeting) |
| Source | Presentation information for the 68th Annual Meeting of the American Society of Hematology; abstract URLs (presentation numbers 3878 and 1815) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Updated clinical trial data from the ongoing Phase 1b trial of docirbrutinib will be presented at the 68th Annual Meeting of the American Society of Hematology.